Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review

Correction: An Automated Phylogenetic Tree-Based Small Subunit rRNA Taxonomy and Alignment Pipeline (STAP)

(2014) Dongying Wu et al.   PLoS One

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

(2013) Elise P. Salerno et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

(2013) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics

(2013) Vassilis Georgoulias et al.   Clinical Lung Cancer

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

(2013) Christopher B Fox et al.   Expert Review of Vaccines

Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial

(2013) Marta Boffito et al.   VACCINE

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

(2013) T Maeda et al.   Blood Cancer Journal

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

(2012) Norihiko Takahashi et al.   CANCER SCIENCE

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

(2012) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+T-cell responses in melanoma patients

(2012) Simone M. Goldinger et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

(2012) Dennis A Revicki et al.   Health and Quality of Life Outcomes

Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide

(2012) Shingo Eikawa et al.   INTERNATIONAL JOURNAL OF CANCER

Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

(2012) Jacob Atsmon et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial

(2012) Olga Pleguezuelos et al.   VACCINE

Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51

(2011) Sócrates Herrera et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

(2011) Vladimir Mulens et al.   Human vaccines & immunotherapeutics

The Vaccine-site Microenvironment Induced by Injection of Incomplete Freundʼs Adjuvant, With or Without Melanoma Peptides

(2011) Rebecca C. Harris et al.   JOURNAL OF IMMUNOTHERAPY

WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient

(2010) Yusuke Oji et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval

(2010) Anri Saitoh et al.   MEDICAL ONCOLOGY

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity

(2010) Barney S. Graham et al.   PLoS One

Vaccine adjuvants: Current challenges and future approaches

(2008) Jennifer H. Wilson-Welder et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease

(2008) P G Maslak et al.   LEUKEMIA